Status: Not yet recruiting
Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration
Trial to Evaluate the Safety and Efficacy of SCAI-005 Ophthalmic solution in Patients with Neovascular Age-related Macular Degeneration. The purpose of this study is to investigate the efficacy, safety and tolerability of SCAI-005 Ophthalmic solution by dose in patients with neovascular Age-related Macular Degeneration (nAMD).
Participants needed: 50
Trial details
Phase: Phase 2Age: 50+Biological sex: AllType: InterventionalSponsor: SCAI TherapeuticsUpdated: May 26, 2026
Eligibility criteria
Adults aged 50 years or older [+4]
Subjects with choroidal neovascularization in the study eye due to causes other... [+9]